Left arm was inflamed; it kind of itched; area was a little swollen; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN), LOSARTAN, ATORVASTATIN, ASCORBIC ACID, TOCOPHERYL ACETATE, XANTOFYL, ZEAXANTHIN, ZINC (AREDS), CALCIUM, VITAMIN D [VITAMIN D NOS], LATANOPROST and DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE (DORZOLAMID + TIMOLOL TRB) for an unknown indication.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen). At the time of the report, VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Feb-2021 and was forwarded to Moderna on 08-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN), LOSARTAN, ATORVASTATIN, ASCORBIC ACID, TOCOPHERYL ACETATE, XANTOFYL, ZEAXANTHIN, ZINC (AREDS), CALCIUM, VITAMIN D [VITAMIN D NOS], LATANOPROST and DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE (DORZOLAMID + TIMOLOL TRB) for an unknown indication.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen). At the time of the report, VACCINATION SITE INFLAMMATION (Left arm was inflamed), VACCINATION SITE PRURITUS (it kind of itched) and VACCINATION SITE SWELLING (area was a little swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Treatment information for the event was provided.